Key takeaways
- Zepbound produced greater average weight loss — 20.2% vs. 13.7% in the head-to-head SURMOUNT-5 trial — but Wegovy has the cardiovascular outcome evidence Zepbound can’t yet match.
- Real out-of-pocket costs depend more on your insurance and pharmacy than the list price.
- Owner reports favor Zepbound on results; for both, the most common complaint is insurance and access, not the medication itself.
The quick verdict
Both medications are FDA-approved for chronic weight management and work on related pathways — Wegovy (semaglutide) targets GLP-1 receptors, while Zepbound (tirzepatide) targets both GLP-1 and GIP receptors. The honest answer is that “better” depends on whether your priority is maximum weight loss, proven heart benefits, cost, or tolerability. Here’s how the evidence breaks down.
What the clinical trials show
This is where most articles hand-wave. We read the actual trials, and the differences are measurable but more nuanced than the marketing suggests.
Head-to-head weight loss data
In the first head-to-head randomized trial directly comparing the two drugs at their maximum tolerated doses, participants on tirzepatide (Zepbound) lost 20.2% of their body weight on average versus 13.7% on semaglutide (Wegovy) at 72 weeks — a real, statistically significant gap. The bigger milestones favored tirzepatide too: about 82% lost at least 10% of their weight, versus about 61% on semaglutide.
Source: SURMOUNT-5 randomized controlled trial, NEJM 2025 (NEJMoa2416394) · 751 participants · 72 weeks · funded by Eli Lilly, Zepbound's maker (disclosed per our methodology)
Wegovy holds one advantage Zepbound can’t yet match: a completed cardiovascular outcomes trial. In the SELECT trial — in people with established cardiovascular disease and overweight or obesity but without diabetes — semaglutide 2.4 mg cut the risk of major adverse cardiac events (cardiovascular death, heart attack, or stroke) by about 20% versus placebo. If you have cardiovascular history, that evidence matters and is worth discussing with your doctor.
Side effects compared
Both share the same core side-effect profile — nausea, constipation, and digestive discomfort, especially during dose increases — and in the head-to-head trial the large majority of participants in both groups tolerated treatment well enough to continue. The practical difference reported by users is timing: most side effects cluster in the first weeks after each dose increase, then ease as the body adapts.
Real monthly cost in 2026
List prices mislead. What you actually pay depends on insurance coverage, manufacturer savings programs, and whether you go through a telehealth provider. Here’s the realistic range — approximate figures as of mid-2026; GLP-1 pricing changes often, so always confirm current costs with the provider and your insurer:
| Wegovy | Zepbound | |
|---|---|---|
| With insurance coverage | $0–$200/mo | $25–$200/mo |
| Cash pay (direct programs) | ≈$499/mo | ≈$349–$499/mo |
| Via telehealth programs | $149–$299/mo + meds | $149–$299/mo + meds |
| Medicare coverage | Limited — see our guide | Limited — see our guide |
Why we recommend them: highest score in our independent rubric for insurance support — the biggest cost factor for both drugs. We may earn a commission if you sign up; this did not affect their score.
What ~900 owner reports reveal
We analyzed roughly 900 comments across seven high-engagement threads in the r/Zepbound and r/WegovyWeightLoss communities (June 2026; patterns paraphrased — we don’t quote individuals). Three findings stood out:
The loudest complaints aren’t about either medication — they’re about insurance. In the largest switching thread we reviewed, insurer-forced formulary switches and prior-authorization paperwork dominated (58 of 103 comments analyzed), far outpacing complaints about side effects. That’s why provider insurance support weighs heavily in our rankings.
Switching outcomes are genuinely individual. Among people forced from Zepbound to Wegovy, more reported worse results than fine ones (13 vs. 9 in that thread) — consistent with Zepbound’s edge in trial data. But the reverse story exists too: in a thread of people switching to Zepbound, several reported they’d done poorly on it and well on semaglutide. Population averages aren’t personal guarantees, in either direction.
Side-effect intensity doesn’t track results. A recurring community question is whether rough side effects mean the drug is “working better.” The consistent answer from owners — including many losing steadily with zero side effects — is no. Trial data agrees: tolerability and efficacy are separate dials.
Considerations if you’re over 60
Older adults face two extra questions: muscle loss and coverage. Research notes that a portion of weight lost on GLP-1s is lean mass, which matters more with age — clinicians typically recommend pairing treatment with resistance exercise and adequate protein. On coverage, traditional Medicare’s rules for weight-loss medications are restrictive and changing; our Medicare and GLP-1 coverage guide covers the current state in detail.
Frequently asked questions
Can I switch from Wegovy to Zepbound?
Yes, switching is common and should be managed by your prescriber, who will determine the equivalent starting dose. Don’t switch doses on your own.
Which one does insurance cover more often?
It varies entirely by plan. Both manufacturers offer savings programs, and several providers in our rankings will check your coverage for both drugs before you commit.
Are compounded versions of these drugs safe?
Compounded semaglutide and tirzepatide were sold widely during the 2022–2025 shortages, but that exception has largely closed and 2026 brought major FDA enforcement against mass-marketed copies. They aren’t FDA-approved and quality varies by pharmacy. We score providers partly on medication sourcing — see our methodology.
- SURMOUNT-5 — tirzepatide vs. semaglutide head-to-head randomized controlled trial, New England Journal of Medicine 2025 (NEJMoa2416394); 751 adults with obesity, 72 weeks, maximum tolerated doses; funded by Eli Lilly (Zepbound's manufacturer)
- SELECT — semaglutide 2.4 mg cardiovascular outcomes trial, New England Journal of Medicine 2023 (NEJMoa2307563); established cardiovascular disease + overweight/obesity without diabetes; ~20% reduction in major adverse cardiovascular events; funded by Novo Nordisk
- FDA prescribing information: Wegovy (semaglutide), Zepbound (tirzepatide)
- Owner-report analysis: ~914 comments across seven high-engagement threads in r/Zepbound and r/WegovyWeightLoss, collected June 12, 2026 — threads analyzed: starting scared · minimal side effects · weird side effects · side effects vs results · insurer-forced switching · switching experiences · clinician lessons. Patterns paraphrased with theme counts; no individual quotes or usernames — see how we source community reports
This article was produced using our 31-point scoring methodology. We analyze published research and consumer reviews; we do not personally test medical products. This is not medical advice — consult a licensed clinician.